Sort
39,280 grants matching “leukemia”
NMR Structural Studies of CBFB and CBFB-SMMHC
$316,620University Of Virginia Charlottesville · R01 · FY2001 · AI
Novel TYRO3 inhibitors for treatment of cancer
$316,619Xiaodong Wang · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Novel TYRO3 inhibitors for treatment of cancer
$316,619Xiaodong Wang · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
PERSISTENT VIRUS INFECTION IN AGED MICE
$316,611Mcp Hahnemann University · R01 · FY2000 · AG
Molecular diagnostic and prognostic signatures for PTCL
$316,581Javeed Iqbal · University Of Nebraska Medical Center · UH3 · FY2019 · CA
CHILDRENS CANCER GROUP
$316,578Children'S Hospital Los Angeles · U10 · FY2001 · CA
GENETIC AND MOLECULAR STUDIES OF NEUROGENESIS
$316,563University Of Oregon · R01 · FY2000 · HD
CMV/CD19 bi-Specific CAR T cells combined with CMV vaccine as post-transplantation immunotherapy for non-Hodgkin lymphoma
$316,549Stephen J Forma · Beckman Research Institute/City Of Hope · P50 · FY2021 · CA
Project 4: Enhancing the Efficacy of Chimeric Antigen Receptor Therapy for B-ALL and DLBCL
$316,522Crystal Mackall · Stanford University · P01 · FY2021 · CA
Project 4: Enhancing the Efficacy of Chimeric Antigen Receptor Therapy for B-ALL and DLBCL
$316,522Crystal Mackall · Stanford University · P01 · FY2023 · CA
Project 4: Enhancing the Efficacy of Chimeric Antigen Receptor Therapy for B-ALL and DLBCL
$316,509Crystal Mackall · Stanford University · P01 · FY2020 · CA
Histologic and Molecular Characterization of Solid Pediatric Tumors
$316,500Maria Tsokos · Division Of Clinical Sciences - Nci · Z01 · FY2008 · CA
Project 4: Enhancing the Efficacy of Chimeric Antigen Receptor Therapy for B-ALL and DLBCL
$316,488Crystal Mackall · Stanford University · P01 · FY2019 · CA
preTCR as an inducer of cell survival and transformation
$316,480Iannis Aifantis · New York University School Of Medicine · R01 · FY2007 · CA
Expression and Function of Tob in T Lymphocytes
$316,479Vassiliki A Boussiotis · Massachusetts General Hospital · R01 · FY2007 · CA
Regulation of cyclin D3 in B lymphocyte development
$316,451Marcus R Clark · University Of Chicago · R01 · FY2010 · GM
HUMAN DENDRITIC CELLS AND THE ONSET OF INNATE AND ADAPTIVE IMMUNITY IN ALLOGENEIC
$316,447James W. Young · Sloan-Kettering Inst Can Research · P01 · FY2008 · CA
Validation of microRNAs as therapeutic targets in hematological malignancies
$316,438Natarajan Muthusamy · Ohio State University · R01 · FY2015 · CA
Novel Immunotherapies for Lymphoid Malignancies
$316,438John C Byrd · Ohio State University · R01 · FY2012 · CA
Validation of microRNAs as therapeutic targets in hematological malignancies
$316,438Guido Marcucci · Ohio State University · R01 · FY2012 · CA
PDLIM2 as a cancer and chemosensitizing target
$316,438Gutian Xiao · University Of Pittsburgh At Pittsburgh · R01 · FY2013 · CA
Role of microRNAs in the regulation of CML stem cell survival and self renewal
$316,438Danilo Perrotti · Ohio State University · R01 · FY2012 · CA
Validation of microRNAs as therapeutic targets in hematological malignancies
$316,438Guido Marcucci · Ohio State University · R01 · FY2011 · CA
Novel Immunotherapies for Lymphoid Malignancies
$316,438John C Byrd · Ohio State University · R01 · FY2016 · CA
Novel Immunotherapies for Lymphoid Malignancies
$316,438John C Byrd · Ohio State University · R01 · FY2015 · CA